Pharmacogenomics--drug disposition, drug targets, and side effects.

By William E. Evans, Howard L. McLeod. New England Journal of Medicine, 2003

1,734 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/69a2a62464ca8e676991935725af5d820cc6034b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

In Oncology

In Pharmacology

Citations in the corpus

Moving towards individualized medicine with pharmacogenomics (2004, background): “During this period, polymorphisms in genes encoding drug transporters and targets were also identified and shown to alter drug respons”
Pharmacogenomics of GPCR Drug Targets (2018, positive): “, cytochrome P450) or those that regulate drug uptake can contribute to altered drug reaction (Evans and McLeod, 2003).”
Pharmacogenomics and individualized drug therapy. (2006, background): “Beta(2)-adrenergic receptor pharmacogenetics.”
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action (2012, background): “Genomics is thought to account for a significant part of interindividual variability (30) in the drug effect, while eliciting consistent intraindividual responses (31).”
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. (2008, background): “From an analysis standpoint, SNPs are convenient because they can be determined at any time and are not affected by the status of the tumor.(24) Much prior work has tested tumor-specific markers without success.”
P-glycoprotein: from genomics to mechanism (2003, background): “In recent reviews (Brinkmann et al., 2001; Saito et al., 2002; Evans and McLeod, 2003; Schwab et al., 2003), a total of 50 SNPs and three insertion/deletion polymorphisms have been reported in the MDR1 gene.”
Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine (2016, background): “Continuous drug monitoring is recommended when prescribing drugs with known serious side effects and narrow therapeutic indexes to avoid unexpected and undesirable outcomes [12].”